Clinicaltrials.gov: [STUDY_ID_REMOVED]  
Title: Study Protocol and Statistical Plan for CS -011-004 IRB#: 19 -0726  
Date: 2 Aug 2019  
  
 Clinical investigation plan CS -011-004 Ver.3.1 
 1 / 38 
 
 
Clinical investigation plan  
 
 
EVALUATION OF CAPI[INVESTIGATOR_726615]: CS -011 
 
Clinical investigation plan number: CS -011-004 
 
Version number: 3.1  Date: August 2, 2019 
 
 
Sponsor: 
Nihon Kohden Corporation  
1-31-[ADDRESS_992330] s. 
 Clinical investigation plan CS -011-004 Ver.3.1 
 2 / [ADDRESS_992331] 2, 2019  3.1 Add ICU in the section 1.3 
  
 Clinical investigation plan CS -011-004 Ver.3.1 
 3 / 38 
 
Synopsis  
 
Title:  Evaluation of Capi[INVESTIGATOR_726616]:  Single -center, cross -sectional study  
 
Subject population:  Adult emergency department (ED ) and intensive care unit (ICU) patients (both 
males and females without regards to ethnic and racial backgrounds) who meet 
the following eligibility criteria will be recruited.  
 
Inclusion criteria  
‚Ä¢ Individuals 18 years of age or older  
‚Ä¢ Patient s who present to the ED  or who are admitted to the ICU of North Shore 
University Hospi[INVESTIGATOR_307]  (NSUH) 
 
Exclusion criteria  
‚Ä¢ Pregnant  
‚Ä¢ Prisoners  
‚Ä¢ Finger, hand or forearm anatomical anomaly or disease that may interfere with 
attaching a pulse oximeter sensor  
‚Ä¢ Patients ‚Äô deemed clinically unstable by [CONTACT_726646]:  Total number of subjects is up to 60.  
 
Study duration:  ‚Ä¢ Expected duration of each subject participation is approximately 15 minutes.  
‚Ä¢ The duration of subject recruitment is anticipated for 6 months.  
‚Ä¢ The total duration of the study (including data collection and analysis) is 
approximately 1 year.  
 
Investigational device: This study will use a non- significant risk  combination of two components  to 
measure Capi[INVESTIGATOR_726617] (CRI) : 
‚Ä¢ Non-FDA-cleared pulse oximeter (OLV -4201A, Nihon Kohden Corporation, 
Tokyo, Japan): OLV -4201A pulse oximeter is intended for use in monitoring 
SpO 2 and pulse rate (PR) using a finger sensor. It conforms to the safety 
standard of IEC  [ZIP_CODE]- 1:2005+A1:2012, and the electromagnetic 
compatibility standard of IEC [ZIP_CODE]-1- 2:2007 and ISO [ZIP_CODE] -2-61:2011  
(clause202). The CRI measurement function is embedded in OLV -4201A.  
 Clinical investigation plan CS -011-004 Ver.3.1 
 4 / 38 
 
‚Ä¢ FDA- cleared SpO 2 sensor probes (TL- 271T3, Nihon Kohden Corporation, 
Tokyo, Japan ): The sensors are disposable and intended for single patient 
use. 
 
Note:  the pulse oximeter is a class II device and is not used for life support or as 
a life sustaining device, thus the risk of this investigational use is considered 
extremely low. Furthermore, the device will not be used for any clinical diagnoses and any data obtained from the device will be blinded from the treating physicians and thus will not have any impact on the patient ‚Äôs clinical care. Therefore, the 
investigational device qualifies as a non- significant risk (NSR) device  and 
does not require an Investigational Device Exemption (IDE) approval  from 
the FDA.  
 
Objectives:  (1) Primary objective  
The primary objective is to evaluate the capability of Capi[INVESTIGATOR_726617] (CRI)  
measured by [CONTACT_726647][INVESTIGATOR_726618] (CRT)  test. Predictive capability of 
CRI needs to be assessed to achieve a goal to provide clinicians with an 
alternative method to the traditional CRT test.  
 (2) Secondary objective(s)  
The secondary objective is to assess the correlation between CRI and CRT 
values. Although both CRI and CRT reflect time required for reperfusion of 
fingertip after the compression, measured absolute numerical values will be 
different since the mechanisms to assess peripheral perfusion are different 
between CRI and CRT.  
 
Endpoint (s): (1) Primary endpoint  
The primary endpoint is the area under the curve (AUC) of the receiver operator 
characteristic (ROC) curve analysis on CRI values to predict the altered 
peripheral perfusion determined with the CRT test. A specific cutoff value for CRI has not yet been determined, then the AUC value will be used to summarize comprehensive capability of CRI to detect the altered peripheral perfusion.  
 (2) Secondary endpoint(s)  
The secondary endpoints include the followings:  
‚Ä¢ Sensitivity and specificity of CRI in differentiating altered peripheral perfusion 
determined with the CRT test. An optimal cutoff value for CRI will be 
 Clinical investigation plan CS -011-004 Ver.3.1 
 5 / 38 
 
determined with the ROC analysis for the primary endpoint.  
‚Ä¢ Pearson‚Äô s or Spearman‚Äô s correlation coeffici ent to assess the correlation 
between CRI and CRT values.  
Table of C ontents 
Revision history  ......................................................................................................................................... [ADDRESS_992332] of Abbreviations  .................................................................................................................................. 9  
1 General  ............................................................................................................................................ 10 
1.1 Introduction ............................................................................................................................... 10 
1.2 Sponsor  ..................................................................................................................................... 10 
1.3 Principal investigator [INVESTIGATOR_726619](s)  .......................................................................... 10 
2 Investigational device ..................................................................................................................... 11 
2.1 Summary description of the investigational device and its intended purpose  ............................ 11 
2.2 Manufacture of the investigational device ................................................................................. 12 
2.3 Name [CONTACT_199316]/type including software version and accessories  ...................... 12 
2.4 Traceability  ................................................................................................................................ 12 
2.5 Intended purpose of the investigational device in this clinical investigation  .............................. 12 
2.6 Populations and indications for which the investigational device is intended ............................ 12 
2.7 Materials of the investigational device contact[CONTACT_726648]  ............................ 13 
2.8 Necessary training and experience needed to use the investigational device .......................... 13 
2.9 Specific medical or surgical procedures involved in the use of the investigational device  ........ 13 
3 Justification for the design of the clinical investigation  ............................................................. 13 
3.1 Evaluation of the results of the relevant pre- clinical testing/assessment carried out to justify the 
use of the investigational device in human subjects  ............................................................................ 13 
3.2 Evaluation of clinical data relevant to this clinical investigation ................................................. 13 
4 Risks and benefits of the investigational device and the clinical investigation  ....................... 14 
4.1 Anticipated clinical benefits  ....................................................................................................... 14 
4.2 Anticipated adverse device effects  ............................................................................................ 14 
4.3 Residual risks associated with the investigational device identified in the risk analysis  ............ 14 
4.4 Risk associated with participation in the clinical investigation ................................................... 14 
4.5 Poss ible interactions with concomitant medical treatments  ...................................................... 14 
4.6 Steps that will be taken to control or mitigate the risks .............................................................. 14 
4.7 Risk-to-benefit rational  .............................................................................................................. 15 
5 Objectives and hypotheses of the clinical investigation  ............................................................ 15 
5.1 Primary and secondary objectives  ............................................................................................ 15 
5.1.1  Primary objective ............................................................................................................... 15 
5.1.2  Secondary objective(s) ...................................................................................................... 15 
 Clinical investigation plan CS -011-004 Ver.3.1 
 6 / 38 
 
5.2 Hypotheses to be tested by [CONTACT_726649]  ............................... 15 
5.3 Claims and intended performance of the investigational device that are to be verified  ............. 15 
5.4 Risks and anticipated adverse device effects to be assessed  .................................................. 15 
6 Design of the clinical investigation  .............................................................................................. 16 
6.1 General  ..................................................................................................................................... 16 
6.1.1  Type of the clinical investigation  ........................................................................................ 16 
6.1.2  Measures to be taken to minimize or avoid bias, including randomization and 
blinding/masking .............................................................................................................................. 16 
6.1.3  Primary and secondary endpoints ...................................................................................... 16 
6.1.4  Methods and timing for assessing, recording and analyzing variables  .............................. 17 
6.1.5  Equipment to be used for assessing, recording and analyzing variables and arrangements 
for monitoring maintenance and calibration...................................................................................... 17 
6.1.6  Any procedures for the replacement of subjects  ................................................................ 17 
6.2 Investigational device(s) and comparator(s) ............................................................................. 18 
6.2.1  Description of the exposure to the investigational device(s) or comparator(s), if used ...... 18 
6.2.2  Justification of the choice of comparator(s)  ........................................................................ [ADDRESS_992333] ‚Äôs participation .............................................................. [ADDRESS_992334] this number (i.e. enrolment period)  ................................ [ADDRESS_992335] compensation  ........................................................................................................ 19 
6.4 Procedures  ................................................................................................................................ 20 
6.4.1  All the clinical- investigation- related procedures that subjects undergo during the study  ... 20 
6.4.2  Activities per formed by [CONTACT_3573] (excluding monitoring)  ........................... 22 
6.4.3  Any known or foreseeable factors that may compromise the outcome of the clinical 
investigation or the interpretation of results  ...................................................................................... 22 
6.5 Monitoring plan  ......................................................................................................................... 23 
7 Statistical considerations .............................................................................................................. 23 
7.1 Statistical design, method and analytical procedures  ............................................................... 23 
7.2 Sample size  .............................................................................................................................. 24 
7.3 The level of significance and the power of the clinical investigation  .......................................... 24 
 Clinical investigation plan CS -011-004 Ver.3.1 
 7 / 38 
 
7.4 Expected drop-out rates  ............................................................................................................ 25 
7.5 Pass/fail criteria to be applied to the results of the clinical investigation ................................... 25 
7.6 Provision for an interim analysis  ............................................................................................... 25 
7.7 Criteria for the termination of the clinical investigation on statistical grounds  ............................ 25 
7.8 Procedures for reporting any deviation(s) from the original statistical plan ............................... 25 
7.9 Specification of subgroups for analysis  ..................................................................................... 25 
7.10 Procedures that take into account all the data  .......................................................................... 25 
7.11 Treatment of missing, unused or spurious data, including drop- outs and withdrawals  .............. 25 
7.12 Exclusion of particular information from the testing of the hypothesis  ....................................... 25 
7.13 In multicenter clinical investigations, the minimum and maximum number of subjects to be 
included for each center ...................................................................................................................... 25 
8 Data management .......................................................................................................................... 26 
8.1 Procedures used for data review, database cleaning, and issuing and resolving data queries  . 26 
8.2 Procedure for verification, validation and securing of electronic clinical data system  ............... 27 
8.3 Procedure for data retention  ..................................................................................................... 27 
8.4 Specified retention period  ......................................................................................................... 27 
8.5 Other aspects of clinical quality assurance ............................................................................... 27 
9 Amendments to the clinical investigation  plan ........................................................................... 28 
10 Deviation from the clinical investigation plan  .......................................................................... 28 
10.1 Statement specifying that the investigator is not allowed to deviate from the CIP  .................... 28 
10.2 Procedures for recording, reporting and analyzing CIP deviations  ........................................... 28 
10.3 Notification requirements and time frame .................................................................................. 28 
10.4 Corrective and preventive actions and principal investigator [INVESTIGATOR_645588] ................ 28 
11 Device accountability  ................................................................................................................. 28 
11.1 Labeling and packaging of the investigational device ............................................................... 28 
11.2 Receipt of the investigational device  ......................................................................................... 29 
11.3 Identification of each investigational device (batch number, serial number or unique code) ..... [ADDRESS_992336] identification  ................................................................................................................. 29 
11.7 Investigational device which is returned/explanted from subject, if applicable .......................... [ADDRESS_992337] and any regional or national regulations  ................................................ 30 
12.3 IRB and/or regulatory authorities  .............................................................................................. [ADDRESS_992338]  ..................................................................................................................... 31 
 Clinical investigation plan CS -011-004 Ver.3.1 
 8 / [ADDRESS_992339] for reporting serious adverse events and serious adverse device effects  . 36 
14.9 Information regarding the data monitoring committee ............................................................... 36 
15 Vulnerable population  ................................................................................................................ 36 
16 Suspension or premature termination of the clinical investigation  ....................................... 36 
16.1 Criteria and arrangements for suspension or premature termination ........................................ 36 
16.2 Criteria for access to and breaking the blinding/masking code in the case of suspension or 
premature termination of the clinical investigation  ............................................................................... [ADDRESS_992340] follow- up ........................................................................................... 37 
17 Publication policy  ....................................................................................................................... 37 
18 Bibliography  ................................................................................................................................ 37 
19 Attachments ................................................................................................................................ 38 
 
  
 Clinical investigation plan CS -011-004 Ver.3.1 
 9 / [ADDRESS_992341] of Abbreviations  
 
CRI Capi[INVESTIGATOR_726620]-significant risk  
¬∞C Degrees Celsius  
¬∞F Degrees Fahrenheit  
SpO [ADDRESS_992342]  
ED Emergency department  
ICU Intensive care unit  
AE Adverse event  
PHI Personal Health Information 
CRF Case Report Form  
 Clinical investigation plan CS -011-004 Ver.3.1 
 10 / 38 
 
1 G eneral  
1.1 I ntroduction  
Capi[INVESTIGATOR_95155] (CRT) test is a simple and noninvasive method typi[INVESTIGATOR_726621]. CRT is defined as the time required for a distal capi[INVESTIGATOR_99996] (e.g., fingertip) to regain its color after having received enough compression to cause blanching [1]. A prolonged CRT (e.g. over 2 seconds) suggests a decrease in peripheral perfusion and is used to identify  hemodynamically compromised 
patients in the critical care setting. Several observational studies have reported the clinical usefulness of CRT and the relevance between prolonged CRT and critical conditions. In intensive care patients, prolonged CRT was as sociated with diminished tissue perfusion as well as an increase in organ dysfunction with high blood 
lactate levels [2]. Prolonged CRT was also associated with the development of severe complications in patients following abdominal surgery [3]. However, the conventional CRT test has limitations in objectivity given that the measurement depends on clinicians ‚Äô subjective visual assessment. Since the repeatability and inter -rater 
agreement of the CRT test has been questioned over the last few decades [4, 5], there is great demand for the creation of objective methods to assess peripheral blood perfusion [5, 6].  
 We developed a new analytic method to assess peripheral blood perfusion quantitatively using pulse oximetry waveforms to provide clinicians with an alternative method to the traditional CRT test. The method calculates the time it takes for blood to return to the fingertip after release from compression by [CONTACT_726650] a normal pulse oximeter sensor attached to a patient ‚Äôs fingertip [7,8]. Since the 
mechanisms to assess peripheral blood perfusion are different from the traditional CRT tests, we differentiate the calculated number by [CONTACT_726651][INVESTIGATOR_726617] (CRI). The CRI measurem ent 
function is embedded in our investigational device OLV -4201A pulse oximeter.  
 
1.2 Sponsor  
‚Ä¢ Nihon Kohden Corporation, 1-31- 4 Nishiochiai Shinjuku- ku, Tokyo, 161- 8560, Japan  
‚Ä¢ Nihon Kohden Innovation Center, [ADDRESS_992343], Cambridge, MA, [ZIP_CODE], [LOCATION_003]  
‚Ä¢ Nihon Kohden America: [ADDRESS_992344], Irvine, CA [ZIP_CODE], [LOCATION_003]  
 The sponsored research agreement for funding this study is to be made by [CONTACT_726652] (NKC).  
 
1.3 Principal investigator [INVESTIGATOR_726619](s)  
‚Ä¢ Principal investigator:  
[INVESTIGATOR_726622] , [ADDRESS_992345], Manhasset, NY, [ZIP_CODE]  
 
‚Ä¢ Investigation site (s) 
 Clinical investigation plan CS -011-004 Ver.3.1 
 11 / 38 
 
Emergency Department  (ED) and Intensive Care Unit (ICU)  
North Shore University Hospi[INVESTIGATOR_307]  (NSUH) 
Northwell Health , [ADDRESS_992346], Manhasset, NY, [ZIP_CODE]  
  
2 Investigational device 
2.1 Summary description of the investigational device and its intended purpose 
This study will use a non- significant risk  combination of two components:  
‚Ä¢ Non-FDA-cleared pulse oximeter (OLV -4201A , Nihon Kohden Corporation, Tokyo, Japan): See Attachment 
1 Operator ‚Äôs Manual of OLV -4201.  OLV-4201A pulse oximeter is intended for use in monitoring SpO 2 and 
pulse rate (PR) using a finger sensor. It conforms to the safety standard of IEC60601 -1:2005+A1:2012, and 
the electromagnetic compatibility standard of IEC [ZIP_CODE]-1- 2:2007 and ISO [ZIP_CODE]-2- 61:2011 (clause202). 
See Attachment 2 and 3 Certificate of Safet y/EMC Test.  
‚Ä¢ FDA- cleared SpO 2 sensor probe (TL -271T3, Nihon Kohden Corporation, Tokyo, Japan; K151080, K120888, 
K080342, K001693, K946175, K945578, K043517, K082785) : See Attachment 4 Operator ‚Äôs Manual of 
SpO 2 sensor probe. The sensor is  disposable and intended for single patient use.  
 
The investigational device passes light of two wavelengths (red: 660 nm, infrared: 940 nm) through the fingertip and measures the light intensity at each wavelength, allowing it to determine the different concentrations of two  
types of hemoglobin (oxy -hemoglobin and deoxy -hemoglobin). The CRI measurement uses a wavelength of 
infrared (940 nm) to trace change of blood volume in the fingertip. To measure CRI, a patient ‚Äôs fingertip with a 
pulse oximeter sensor probe attached is briefly compressed by [CONTACT_726653]. The light intensity transmitted through the fingertip increases during compression as blood, which is the major absorber of the light, is squeezed out of the fingertip. The compression phase is followed by [CONTACT_726654]. The curve describing the recovery phase of the intensity waveform is modeled as an exponential decay using the least squares method. The time for returning to a predetermine d level of the intensity is calculated as CRI (Figure 1). The detailed operation of the CRI function 
of OLV -4201 A is described in Attachment 5 Operator ‚Äôs Manual of the CRI function.  
 
Figure 1:  Calculation of CRI using a pulse oximeter waveform  

 Clinical investigation plan CS -011-004 Ver.3.1 
 12 / 38 
 
 
Note:  the pulse oximeter is a class II device and is not used for life support or as a life sustaining device, thus 
the risk of this investigational use is considered extremely low. Furthermore, the device will not be used for any 
clinical diagnoses and any data obtained from the device will be blinded from the treating physician and thus will not have any impact on the patient ‚Äôs clinical care. Therefore, the investigational device qualifies as a non-
significant risk (NSR) device and does not require an Investigational Device Exemption (IDE) approval  
from the FDA.  
 
2.2 M anufacture of the investigational device 
Manufacture: Nihon Kohden Corporation  
Address: 1 -31-4 Nishiochiai Shinjuku- ku, Tokyo, 161 -8560, Japan  
 
2.3 N ame or number of the model/type including software version and accessories  
(1) Model number: OLV-4201A  
(2) Name: [CONTACT_726669]  
(3) Software version: 01- 06 
(4) Composition  
No. Name [CONTACT_726670]  
1 Pulse Oximeter  OLV-4201A  
 
(5) Accessories and disposables  
No. Name [CONTACT_726670]  
[ADDRESS_992347]  JL-400T  
3 Disposable SpO 2 sensor probe TL-271T 3 
 
2.4 T raceability  
‚Ä¢ OLV-4201A  Pulse Oximeter: identify with assigned serial numbers  
‚Ä¢ TL- 271T3 SpO 2 sensor probe: identify with assigned lot numbers  
 
2.5 I ntended purpose of the investigational device in this clinical investigation  
‚Ä¢ M easurement of CRI  
 
2.6 Populations and indications for which the investigational device is intended 
‚Ä¢ Adult ED and ICU patients  both males and females  aged 18 years or older  
 
 Clinical investigation plan CS -011-004 Ver.3.1 
 13 / [ADDRESS_992348] with tissues is as follows:  
 
TL-271T3 SpO2 sensor probe  
Name [CONTACT_726671] [CONTACT_726655].  
 
2.8 Necessary training and experience needed to use the investigational device 
Investigators will be trained by [CONTACT_726656]‚Äôs manual of the investigational device.  
 
2.9 Specific medical or surgical procedures involved in the use of the investigational device  
There is no medical nor surgical procedure involved in the use of the investigational device.  
 
3 J ustification for the design of the clinical investigation 
3.1 Evaluation of the results of the relevant pre-clinical testing/assessment carried out to justify 
the use of the investigational device in human subjects  
OLV-4201A Pulse Oximeter  conforms to the safety standard of IEC60601- 1:2005+A1:2012, and the 
electromagnetic compatibility standard of IEC [ZIP_CODE]-1- 2:2007 and ISO [ZIP_CODE]-2- 61:2011(clause202). See 
Attachment 2 and 3 Certificate of Safety/EMC Test . The part of the investigational device that will be in contact 
[CONTACT_726657] -cleared T L-271T3 SpO 2 probe. There has been no issue regarding 
biocompatibility of the material of the SpO 2 probe described in the section 2.7. Therefore, the use of the 
investigational device in human subjects in this clinical investigation is considered to be justified. 
 
3.2 Evaluation of clinical data relevant to this clinical investigation  
Attachment 6  is a report of a previous clinical study conducted at the ED of NSUH.  In this preliminary clinical 
study, the term ‚ÄúBlood Refill Time (BRT) ‚Äù was used, which is the same as CRI, and a protot ype device was used 
to measure BRT.  The prototype device is a non -FDA- cleared pulse oximeter (OLV -3100, Nihon Kohden 
Corporation, Tokyo, Japan) which is a previous model of OLV -[ADDRESS_992349] whether  the visual CRT was 
greater than 2.0 seconds was 0.84 (95% CI 0.70- 0.98).  There was a strong correlation between BRT and CRT  
(r=0.723, p<0.001). The results suggest that BRT measurements with the prototype device successfully 
identified subjects with altered peripheral perfusion determined by [CONTACT_726658] . 
 Clinical investigation plan CS -011-004 Ver.3.1 
 14 / [ADDRESS_992350] since the applied part of the investigational device (TL-271T3 SpO
2 sensor probe) is equivalent to standard pulse oximeter sensors and has a FDA approval . A well -
known potential adverse effect of pulse oximeters is thermal injuries due to temperature rise at the applied part  
of the sensor.  
 
4.3 R esidual risks associated with the investigational device identified in the risk analysis  
There is no residual risk associated with the investigational device  which is judged unacceptable.  
 
4.4 R isk associated with participation in the clinical investigation  
There is a potential risk of breach of confidentiality, which will be minimized by [CONTACT_726659] 8 ‚Äú Data management ‚Äù of this CIP. 
The study procedures are no greater than minimal risk.  The pulse oximeter is a class II device and is not used 
for life support or as a life sustaining device, thus the risk of this investigational use is considered extremely low. Furthermore, the device will not be used for any clinical diagnoses and any data obtained from the device will be blinded from treating physician s and thus will not have any impact on the subject ‚Äôs clinical care . The 
application of the senso r probe on the subject ‚Äôs finger is not expected to cause pain. If the study procedure 
becomes too uncomfortable, the procedure will be stopped immediately. The investigator (qualified ED physician) will assess the clinical status of the subject prior to enrollment to determine eligibility when the subject is recruited.  
 
4.5 Possible interactions with concomitant medical treatments  
There is no possible interaction with concomitant medical treatments.  
 
4.6 Steps that will be taken to control or mitigate the risks  
All data and records generated during this study will be kept confidentially in accordance with policies  of the 
study site(s)  and HIPAA on subject privacy, and the investigator and other site personnel will not use such data 
and records for any purpose other than conducting the study. All subjects will be given a unique study number.  
The PI [INVESTIGATOR_726623]. The study team will report to the PI [INVESTIGATOR_726624] , and the PI [INVESTIGATOR_726625] . 
Thermal injuries which are the potential adverse effect of the pulse oximeter will be assessed after the measurements with the investigational device.  
 Clinical investigation plan CS -011-004 Ver.3.1 
 15 / [ADDRESS_992351]. Receiver operator characteristic (ROC) curve analysis 
will be performed and area under the curve (AUC) will be calculated for this objective. An optimal cutoff value 
for CRI will be determined with the ROC analysis and the sensitivity and the specificity in differentiating altered peripheral perfusion will also be calculated.  
 
5.1.2  Secondary objective(s)  
The secondary objective is to assess the correlation between CRI and CRT values. Although both CRI and CRT reflect time required for reperfusion of fingertip after the compression, measured absolute numerical values will be different since the mechanisms to assess peripheral perfusion are different between CRI and CRT. Pearson ‚Äôs correlation coefficient will be calculated to assess the correlation between CRI and CRT 
values. If the values are not normally distributed, Spearman‚Äôs correlation coefficient will be used instead.  
 
5.[ADDRESS_992352] . 
 
5.3 C laims and intended performance of the investigational device that are to be verified 
(1) Capi[INVESTIGATOR_726617] (CRI)  
‚Ä¢ Display range: 0.1 ~ 99.9 seconds  
 *CRI will not be claimed as an intended for use in a regulatory application for FDA clearance of OLV -
4201A Pulse Oximeter . CRI will be included in the regulatory application as an index intended for clinical 
research only, not for diagnosis.  
 
5.4 R isks and anticipated adverse device effects to be assessed 
(1) Thermal injuries due to temperature rise at the applied part  of the sensor probe  
 
 Clinical investigation plan CS -011-004 Ver.3.1 
 16 / 38 
 
6 D esign of the clinical investigation  
6.1 G eneral  
6.1.1  Type of the clinical investigation  
Single -center, cross -sectional study : 
In this clinical investigation, CRI and CRT measured at a same time point for each will be compared.  
 
6.1.2  Measures  to be taken to minimize or avoid bias, including randomization and blinding/masking 
‚Ä¢ The investigator who will measure the visual CRT will be blinded from the CRI values measured with 
the investigational device.  
‚Ä¢ CRI and CRT measurements will be alternately  repeated for [ADDRESS_992353].  
 
6.1.3  Primary and secondary endpoints  
(1) Primary endpoint  
The primary endpoint is the area under the curve (AUC) of the receiver operator characteristic (ROC) curve 
analysis on CRI values to predict the altered peripheral perfusion determined with the CRT test. A specific 
cutoff value for CRI has not yet been determined, then the AUC value will be used to summarize comprehensive capability of CRI to detect the altered peripheral perfusion. Procedures of the measurement of CRI and CRT, and statistical methods are described in the section 6.4 " Procedures ‚Äù and the section 7 
‚ÄúStatistical considerations ‚Äù, respectively.  
 
(2) Secondary endpoints  
The secondary endpoints include the followings:  
‚Ä¢ Sensitivity and specificity of CRI in differentiating altered peripheral perfusion determined with the CRT 
test. An optimal cutoff value for CRI will be determined with the ROC analysis for the primary endpoint.  
‚Ä¢ Pearson‚Äô s or Spearman‚Äô s correlation coefficient to assess the correlation between CRI and CRT values.  
  
 Clinical investigation plan CS -011-004 Ver.3.1 
 17 / 38 
 
6.1.4  Methods and timing for assessing, recording and analyzing variables  
The study team will perform assessments and measurements according to the following table:  
 
Study Phase  Screening 
and 
registration Study 
measurement  
at the bedside  Follow up  
Review the inclusion  and the exclusion criteria  X   
Informed consent/ assent  X   
Assigning a unique study subject number  X   
Measurements for subject ‚Äôs basal 
characteristics   X  
Applying a SpO [ADDRESS_992354]‚Äôs basal 
characteristics    X 
 The study procedures listed in the table are described in the section 6.3 ‚ÄúSubjects ‚Äù, the section 6.4 
‚ÄúProcedures ‚Äù and the section 13 ‚ÄúInformed consent process ‚Äù. 
 
6.1.5  Equipment to be used for assessing, recording and analyzing variables and arrangements for monitoring maintenance and calibration  
Equipment to be used in this  study  are described in the section 2 ‚ÄúInvestigational device ‚Äù and the section 6.4 
‚ÄúProcedures ‚Äù. 
 
6.1.[ADDRESS_992355] 54 subjects to be analyzed as described in the section 7.2 ‚ÄúSample size ‚Äù. 
 
 Clinical investigation plan CS -011-004 Ver.3.1 
 18 / 38 
 
6.2 I nvestigational device(s) and comparator(s)  
6.2.1  Description of the exposure to the investigational device(s) or comparator(s), if used  
(1) Investigational device  
The SpO2 sensor probe will be applied to a subject ‚Äôs fingertip.  
 
(2) Comparator  
The comparator is the visual CRT. There is no physical exposure for the CRT test.  
 
6.2.2  Justification of the choice of comparator(s)  
The comparator is the visual CRT, which is typi[INVESTIGATOR_726626].  
The CRI measurement has been developed to assess peripheral blood perfusion quantitatively as an 
alternative method to the visual CRT test.  Therefore, comparisons between CRI  and CRT need to be 
performed.  
 
6.2.[ADDRESS_992356] information of patient ‚Äôs basal characteristics 
as listed below:  
‚Ä¢ Noninvasive blood pressure 
‚Ä¢ SpO 2 
‚Ä¢ Pulse rate or heart rate  
‚Ä¢ Respi[INVESTIGATOR_697] (if available)  
‚Ä¢ Body temperature  
 
There is no medication to be used during the investigation.  
 
6.2.4  Number of investigational devices to be used  
‚Ä¢ OLV -4201A Pulse Oximeter:  1 unit  
‚Ä¢ TL- 271T3 SpO 2 sensor probe:  [ADDRESS_992357] selection  
Adult ED and ICU patients (both males and females without regard to diverse ethnic and racial backgrounds) 
who meet the following inclusion criteria will be recruited.  
‚Ä¢ Individuals 18 years of age or older  
‚Ä¢ Patients who present to the ED or who are admitted to the ICU of North Shore University Hospi[INVESTIGATOR_307]  
(NSUH)  
 
 Clinical investigation plan CS -011-004 Ver.3.1 
 19 / [ADDRESS_992358] selection  
‚Ä¢ Pregnant  
‚Ä¢ Prisoners  
‚Ä¢ Finger, hand or forearm anatomical anomaly or disease that may interfere with attaching a pulse 
oximeter sensor  
‚Ä¢ Patients ‚Äô deemed clinically unstable by [CONTACT_6098]  
 
6.3.[ADDRESS_992359] ‚Äôs withdrawal will continue to be used and analyzed. No further data 
will be collected after the subject ‚Äôs withdrawal.  
 
6.3.4  Point of enrollment  
Adult patients who present to the ED of NSUH who meet the eligibility criteria will be recruited. Importantly, 
patients will only be approached who are physically available to participate in the study, as to not delay or interrupt the patient ‚Äôs care for recruitment. Informed consent will be obtained directly from the subject prior to 
all procedures.  Then, a unique study subject number will be assigned, and the subject will be registered for 
this study.  
 
6.3.5  Total expected duration of the clinical investigation  
The duration of the study (including data collection and analysis) is approximately [ADDRESS_992360] ‚Äôs participation  
Expected duration of each subject ‚Äôs participation is approximately 15 minutes.  
 
6.3.7  Number of subjects required to be included in the clinical investigation  
Total number of subjects is up to 60. Detail of the required sample size calculation is described in the section 
7.2 ‚ÄúSample size ‚Äù. 
 
6.3.[ADDRESS_992361] this number (i.e. enrolment period)  
The duration of subject enrollment is anticipated for [ADDRESS_992362] will receive a $[ADDRESS_992363] as compensation for their participation in this study.  
 Clinical investigation plan CS -011-004 Ver.3.1 
 20 / [ADDRESS_992364] inserted in the device. Data recoded on paper forms will be entered into REDCap so that it can be  
analyzed.  
 Patient ‚Äôs basal characteristics will be collected as shown below. Noninvasive blood pressure, SpO
2, pulse 
rate, respi[INVESTIGATOR_726627] a standard patient monitor used in the ED.  
 
Obtained from medical record:  
‚Ä¢ Age 
‚Ä¢ Gender  
‚Ä¢ Race  
‚Ä¢ Height  
‚Ä¢ Body weight  
‚Ä¢ Past general medical history (diabetes mellitus, hypertension, smoking, heart disease, lung disease, 
others)  
‚Ä¢ Initial vital sign data (blood pressure, SpO 2, pulse rate/heart rate, respi[INVESTIGATOR_37499])  
‚Ä¢ Core body temperature (if available)  
‚Ä¢ Red blood cell count (RBC), Hematocrit (Ht) and Hemoglobin (Hb) (if available)  
‚Ä¢ Lab data: Blood lactate levels, Cre/BUN and TP/Alb (if available)  
‚Ä¢ Primary diagnosis  
‚Ä¢ Disposition (Discharged home, admitted, left against medical advice, skilled nursing facility, other hospi[INVESTIGATOR_307], expi[INVESTIGATOR_5697], unknown or ot her) 
‚Ä¢ Time of events (ED arrival, ED encounter, ED discharge and admission, etc.)  
 
Obtained at the bedside:  
‚Ä¢ CRT 
‚Ä¢ CRI 
‚Ä¢ Noninvasive blood pressure 
‚Ä¢ SpO 2 
‚Ä¢ Pulse rate or heart rate  
‚Ä¢ Respi[INVESTIGATOR_697] (if available)  
‚Ä¢ Fitzpatrick skin tone scale  
 Clinical investigation plan CS -011-004 Ver.3.1 
 21 / 38 
 
 
‚Ä¢ Body temperature (axillary)  
‚Ä¢ Forearm and fingertip temperatures  
‚Ä¢ Room temperature  
 
The surface temperature of the patient ‚Äôs hand will be measured by a non- contact [CONTACT_548264]. To 
address the reliability of the subjective assessment of peripheral perfusion by [CONTACT_74169], we will also 
measure forearm -to-fingertip skin temperature difference (Tskin- diff), as well as central -to-fingertip 
temperature difference (Tc -diff). The Tskin- diff will be obtained from the index/middle finger temperature and 
the temperature on the radial side of the forearm, midway between the elbow and the wrist.  
 The CRT and the CRI measurements will be conducted with following methods for each subject in a relaxed position (seated or lying down) with relaxed hands. The subject ‚Äôs most accessible hand (right or left) will be 
used. Each measurement will be performed alternately and will be repeated three times each for a total of six compressions per subject. If the subject is wearing nail polish, the investigator will measure CRI/CRT aft er 
removing the subject ‚Äôs nail polish. If the subject is wearing a ring on their finger, CRI/CRT will be measured 
after removing the ring(s).  
 Visual CRT measurement using a stopwatch  
An investigator (an ED physician) will compress the fingertip of the su bject ‚Äôs index or middle finger for five 
seconds, signaled by ‚Äú start compression ‚Äù and ‚Äúrelease compression ‚Äù beep sounds. When the fingertip is 
released from the compression, the investigator will begin the visual CRT measurement. The investigator will hold a stopwatch in the hand that does not perform the compression and use this stopwatch to measure CRT.  
 CRI measurement by [CONTACT_726660]
[ADDRESS_992365] ‚Äôs fingertip for five seconds 
by [CONTACT_093]‚Äô s finger as same way of the traditional CRT test. The sensor is flexible and thus, the 
investigator is able to compress the fingertip by [CONTACT_726661] (Figure 2) . The compression will be 
performed with signals from the device, and then the device will measure CRI.  

 Clinical investigation plan CS -011-004 Ver.3.1 
 22 / 38 
 
 
Figure 2:  Compression for the CRI measurement  
 
The investigator will confirm the sensor probe is properly applied to the fingertip by [CONTACT_726662]. With proper application of the sensor probe, the measurement waveform is convex upward as shown in Figure 3. If the sensor probe is not properly applied, the investigator will replace the sensor probe.  
 
Figure 3:  Proper shape of the CRI measurement waveform  
 
The investigator will be blinded from the measured value of the CRI measurement.  
 All subjects are free to withdraw from the study at any time and for any reason. The investigators will immediately discontinue any procedures and remove any research instruments from the subject. Data collected until the subject ‚Äôs point of withdrawal from the study will be analyzed. The estimated duration of the 
subject ‚Äôs participation is approximately 15 minutes in total.  
  
6.4.2  Activities performed by [CONTACT_3573] (excluding monitoring)  
There is no activity performed by [CONTACT_3573].  
 
6.4.3  Any known or foreseeable factors that may compromise the outcome of the clinical investigation or 
the interpretation of results  
‚Ä¢ Improper application of the sensor probe to the fingertip will cause inappropriate results of the 
measurement. The investigator will confirm the sensor probe is properly applied to the fingertip with 
the procedure described in the section 6.4.1. If the sensor probe is not properly applied, the 
investigator will replace the sensor probe.  
 

 Clinical investigation plan CS -011-004 Ver.3.1 
 23 / [ADDRESS_992366] to the IRB. 
CIP changes will not be implemented prior to IRB approval unless necessary to eliminate apparent i mmediate 
hazards to the research subjects. In such a case, the IRB will be promptly informed of the change following implementation.  
 The sponsor and/or representative may conduct periodic on- site monitoring visits during the course of the study, 
including  study initiation and close -out to ensure appropriate documentation is present and complete d. The 
investigator will permit study -related monitoring, audits, and inspections  of all study related documents (e.g. 
source documents, regulatory documents, data collection instruments, study data etc.) by [CONTACT_1201], the sponsor, government regulatory bodies, and compliance and quality assurance groups  of the study site . The investigator 
will ensure the capability for inspections of applicable study -related facilities . 
 Participation as an investigator in this study implies acceptance of potential inspection by [CONTACT_726663]. 
 
[ADDRESS_992367] deviations, 95% confidence intervals, medians, and interquar tile ranges.  The mean of the three repeated CRI  and CRT measurements will be considered as the 
values for each subject.  
 The primary and secondary endpoints are described in the section 6.1.3. Receiver operator characteristic (ROC) curve analysis will be performed and area under the curve (AUC) will be calculated to demonstrate capability of CRI to predict altered peripheral perfusion determined with the CRT test. An optimal cutoff value for CRI will be determined with the ROC analysis and the sensitivity and the specificity in differentiating altered peripheral perfusion will be calculated. Pearson‚Äô s, or Spearman‚Äô s correlation coefficient will be calculated to assess the 
correlation between CRI and CRT values.  
 
 Clinical investigation plan CS -011-004 Ver.3.1 
 24 / [ADDRESS_992368]. Sample size for subjects with altered peripheral perfusion required to obtain desired AUC is calculated with the following equation [9]:  
 
ùëõùëõ=  ùëçùëçùõºùõº
22√óùëâùëâ(ùê¥ùê¥ùê¥ùê¥ùê¥ùê¥ )
ùëëùëë2 
 where, Z is the standard normal deviate determined with probability of type I error: Œ±, d is the desired width of 
one-half of the confidence interval (CI), and V(AUC)  is variance of AUC which is derived from the following 
equation [10]:  
 
ùëâùëâ(ùê¥ùê¥ùê¥ùê¥ùê¥ùê¥ ) = (0.0099 √óùëíùëí‚àíùëéùëé22‚ÅÑ) √ó{(5ùëéùëé2+ 8)+ (ùëéùëé2+ 8)/ùúÖùúÖ } 
 where,  ùëéùëé =ùúëùúë
‚àí1(ùê¥ùê¥ùê¥ùê¥ùê¥ùê¥ ) √ó 1. 414; ùúëùúë‚àí[ADDRESS_992369] cumulative normal distribution; and ùúÖùúÖ is the ratio 
of the number of subjects without the altered peripheral perfusion to the number of subjects with the altered peripheral perfusion. Based upon our preliminary data:  
‚Ä¢ The prevalence of the subjects with altered peripheral perfusion is expected to be 30 %, and then ùúÖùúÖ 
is 2.33. 
‚Ä¢ We hypothesize that the AUC will be 0.84, and then ùëéùëé=ùúëùúë
‚àí1(0.84)√ó 1. 414 = 1. 406.  
 Therefore, V(AUC)  can be calculated as follow:  
 
ùëâùëâ(ùê¥ùê¥ùê¥ùê¥ùê¥ùê¥ )=ÔøΩ0.0099 √óùëíùëí‚àí1.[ZIP_CODE]‚ÅÑÔøΩ√ó{(5 √ó 1.4062+ 8)+ (1.4062+ 8)/2.33 }= 0.[ADDRESS_992370] 0.70 which is considered as fair  [11], one-half of the CI: d  should be 0.14 with the 
hypothesized AUC of 0.84. At the significance level of 5% (probability of type I error: Œ± = 0.05), the number of 
subjects with altered peripheral perfusion is derived as:  
 
ùëõùëõ=  ùëçùëçùõºùõº
22√óùëâùëâ(ùê¥ùê¥ùê¥ùê¥ùê¥ùê¥ )
ùëëùëë2=1.962√ó 0.0816
0.142=15.99‚âà16 
 The total number of required sample size given by ùëõùëõ(1 +ùúÖùúÖ) is 54. Considering possible early withdrawals of 
subjects, we plan to recruit up to 60 subjects to achieve 54 evaluable subjects (1 0% of drop- out rate). 
 
7.3 T he level of significance and the power of the clinical investigation 
All statistical tests will be assessed at  the significance level of 5% (probability of type I error: Œ± = 0.05) . 
 
 Clinical investigation plan CS -011-004 Ver.3.1 
 25 / 38 
 
7.4 Expected drop-out rates  
Although the drop -out rate for this study is  unknown,  relatively high drop- out rate can be expected since the 
study site is the ED and the subjects may need early withdrawals due to disposition (admission to the hospi[INVESTIGATOR_726628]). Therefore, we use 10% of drop -out rate and will recruit up to [ADDRESS_992371] s to achieve 5 4 evaluable 
subjects . 
 
7.5 Pass/fail criteria to be applied to the results of the clinical investigation  
The hypothesis to be tested in this study is that CRI is capable to detect subjects with altered peripheral 
perfusion determined with the CRT test, as described in the section 5.2.  A criterion to accept the hypothesis is 
that the AUC  value described in the section 6.1.3 (1) ‚ÄúPrimary endpoint ‚Äù is at least 0.70 which is considered as 
fair [11].  
 
7.6 Provision for an interim analysis  
No interim analysis is planned. 
 
7.7 Criteria for the termination of the clinical investigation on statistical grounds  
As no interim statistical analysis is planned, no criteria for the termination of the study is defined.  
 
7.8 Procedures for reporting any deviation(s) from the original statistical plan 
Any modification to the statistical analysis plan will be documented in the final study report if applicable.  
 
7.9 Specification of subgroups for analysis  
Not applicable.  
 
7.10 Procedures that take into account all the data  
Not applicable. This study is the observational study and no allocation of subjects is planned.  
 
7.11 Treatment of missing, unused or spurious data, including drop-outs and withdrawals  
‚Ä¢ Data collected up to the point of the subject ‚Äôs withdrawal will continue to be used and analyzed.  
‚Ä¢ If just one value of CRI /CRT  out of the three repeated measurements is missing, the mean of the 
remaining two values will be used as the value for the subject.  
 
7.12 Exclusion of particular information from the testing of the hypothesis 
‚Ä¢ Data of a subject in which two or more values of CRI/CRT out of the three repeated measurements are 
missing will be excluded from the analysis.  
 
7.13 In multicenter clinical investigations, the minimum and maximum number of subjects to be 
 Clinical investigation plan CS -011-004 Ver.3.1 
 26 / 38 
 
included for each center  
Not applicable.  
 
8 D ata management  
8.1 Procedures used for data review, database cleaning, and issuing and resolving data queries  
(1) Identification of source document and source data  
All data and information obtained in the study will be recorded on paper forms  of case report form (CRF) . 
The CRFs are considered as original source document s and the data recorded in the source document s is 
considered as original source data.  
 
(2) Case Report Form  (CRF) 
The CRFs are  the primary data collection instrument s for the study. All data requested on the CRF s must 
be recorded. All missing data must be explained. If a space on the CRF is left blank because the procedure was not done, or the question was not asked, write ‚ÄúN/D‚Äù. If the item is not applicable to the individual case, 
write ‚ÄúN/A‚Äù. All entries should be printed legibly in ink. If any entry error has been made, to correct such an 
error, draw a single straight line through the incorrect entry and enter the correct data above it. All such changes must be initialed and dated. DO NOT ERASE OR WHITE OUT ERRORS.  For clarification of 
illegible or uncertain entries, print the clarification above the item, then initial and date it.  
The PI [INVESTIGATOR_726629] ‚Äôs CRF 
and related documents. The PI [INVESTIGATOR_726630].  
 (3) Confidentiality  
Information about study subjects will be kept confidential and managed according to the requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA). Those regulations require a signed subject authorization informing the subject of the following:  
‚Ä¢ What protected health information (PHI) will be collected from subjects in this study  
‚Ä¢ Who will have access to that information and why  
‚Ä¢ Who will use or disclose that information  
‚Ä¢ The rights of a research subject to revoke their authorization for use of their PHI  
 In the event that a subject revokes authorization to collect or use PHI, the investigator, by [CONTACT_5151], retains 
the ability to use all information collected prior to the revocation of subject authorization. For subjects that have revoked authorization to collect or use PHI, attempts should be made to obtain permission to collect at least vital status (i.e. that the subject is alive) at the end of their scheduled study period.  (4) Data review  
The PI [INVESTIGATOR_726631]. The PI [INVESTIGATOR_726632] -011-004 Ver.3.1 
 27 / [ADDRESS_992372] data will be stored in a locked research office at North Shore University Hospi[INVESTIGATOR_3491]/or The Feinstein Institute for Medical Research. This data will also be input into the secure database REDCap, with access granted to study investigators only.  
 When data is sent out of the Northwell Health system to the sponsor, the data shall be de- identified and the 
data file will be encrypted. In this data file, each subject will be assigned a unique study subject number. No 
names or other direct identifiers will be included in the data file. The date when the data was collected and the information on past or current medical history are the only indirect identifiers that will be included in the data file. 
Only the PI  [INVESTIGATOR_562666] a list that links the study subject numbers that are sent to the s ponsor to the original 
subject information. This list will remain stored in the locked research office.  
 Any study records that identify subjects will be kept private. Participants will not be identified in publications disclosed outside of Northwell Health, except as detailed below.  Investigators will share information collected 
from this research study with:  
‚Ä¢ Study sponsor and/or its agents,  
‚Ä¢ Other researchers,  
‚Ä¢ Regulatory agencies, such as the Food and Drug Administration (FDA) and the Department of Health 
and Human Services (DHHS), and  
‚Ä¢ Clinical staff not involved in the study who may be involved in the participant's treatment.  
 
8.4 Specified retention period 
The investigator and the sponsor shall  retain all the records  of the study  during the study  and for a period of 2 
years after the latter of the following two dates:  
‚Ä¢ The date on which the study i s terminated or completed  
‚Ä¢ The date that the records are no longer required for purposes of supporting applications for FDA clearance of the investigational device.  
 
8.5 Other aspects of clinical quality assurance 
Not applicable.  
 Clinical investigation plan CS -011-004 Ver.3.1 
 28 / [ADDRESS_992373] be recorded and reported. The PI [INVESTIGATOR_1238]/or the sponsor will warn the investigator of the importance to respect the CIP. An investigator who continuously violates the CIP despi[INVESTIGATOR_726633].  
 
11 D evice accountability 
11.1 Labeling and packaging of the investigational device 
The study device or its immediate package will bear a label with the following information:  
‚Ä¢ The name [CONTACT_29773], packer, or distributor  
 Clinical investigation plan CS -011-004 Ver.3.1 
 29 / 38 
 
‚Ä¢ The quantity of contents, if appropriate  
‚Ä¢ The stateme nt, "CAUTION -- Investigational device. Limited by [CONTACT_4496] (or [LOCATION_002]) law to 
investigational use."  
 
The label will also describe all relevant contraindications, hazards, adverse effects, interfering substances or devices, warnings, and precautions,  if applicable. The labeling of the device  will not contain any false or 
misleading statements nor imply that the device is safe or effective for the purposes being investigated.  
 The study device will be packaged in accordance with the manufacturer ‚Äôs reco mmendations. The sensor probes 
will be shipped as bulk orders of 24 probes individually packaged. Only one probe will be used for each patient, 
and then it will be discarded.  
 
11.2 R eceipt of the investigational device  
Upon receipt of the investigational  device supplies, an inventory will be performed, and a device tracking log 
will be filled out and signed by [CONTACT_726664]‚Äô s carrier. Any damaged 
or unusable devices will be documented in the study files. The investi gator will notify the sponsor  of any 
damaged or unusable devices that were supplied to the investigator ‚Äôs site.  
 
11.3 Identification of each investigational device (batch number, serial number or unique code)  
Each investigational device will be identified with the following numbers as described in the section 2.4 ‚ÄúTraceability ‚Äù: 
‚Ä¢ OLV-4201A  Pulse Oximeter: identify with assigned serial numbers  
‚Ä¢ TL- 271T3 SpO2 sensor probe: identify with assigned lot numbers  
 
11.[ADDRESS_992374] be used only for the purpose of this study . The OLV -4201A Pulse Oximeter  will be cleaned following the manufactures instructions 
(cleaned by [CONTACT_726665] a mild detergent), and the standard hygiene and infection control procedure in the ED.  
The SpO [ADDRESS_992375] ‚Äôs finger will be properly disposed after each 
use. The device will immediately be returned to the locked research office at N SUH  and/or FIMR  when not in 
use. The research team will follow product instructions and operator ‚Äôs manuals. There are no specific storage 
requirements nor special handling requirements during storage for the study device.  
 
11.[ADDRESS_992376] 
 Clinical investigation plan CS -011-004 Ver.3.1 
 30 / [ADDRESS_992377], the dates of using the dev ice are also traceable.  
 
11.7 I nvestigational device which is  returned/explanted from subject, if applicable 
Not applicable.  
 
11.[ADDRESS_992378] and any regional or national regulations  
This study is  to be conducted in accordance with US and international standards of Good Clinical Practice: 
International Conference on Harmonization ICHE6, ISO [ZIP_CODE], the Code of Federal Regulations Title 21 parts 
803 and 812, and other applicable government regulations and institutional research policies and procedures.  
 
12.3 IRB and/or regulatory authorities  
This CIP and any amendments  on the CIP  will be submitted to the Northwell Health IRB for formal approval of 
the study conduct. The decision of the IRB concerning the conduct of the study will be made in writing to the investigator and a copy of this decision will be provided to the sponsor before commencement of this study.  
 All subjects for this study will be provided a consent form describing this study and providing sufficient information for subjects to make an informed decision about their participation in this study. This consent form will be submitted with the CIP for review and approval by [CONTACT_14884]. The formal consent of a subject, 
using the IRB -approved consent form, must be obtained before that subject undergoes any study procedures. 
The consent form must be signed by [CONTACT_24484] -designated research professional obtaining 
the consent. A waiver of documentation of consent will be used for any subjects that have a physical limitation 
preventing them from signing the consent form but have the ability to understand and express a reasoned choice. In this case, HIPAA authorization will be obtained verbally, and only in cases where ther e is a physical limitation 
preventing the subject from signing his/her name. Both the waiver of documentation of consent and the verbal HIPAA authorization will be documented in the enrollment note.  
 
 Clinical investigation plan CS -011-004 Ver.3.1 
 31 / [ADDRESS_992379] a physical limitation preventing them from signing the consent form. The consent process will be performed as follows:  
(1) The subject will be given consent forms to read and be given an opportunity to ask questions. If the 
subject has a visual impairment, the consent will be read to them.  
(2) One impartial witness will be present during the entire informed consent discussion.  
(3) After the written consent is provided to the subject, if capable of doing so, the subject will sign or mark an X to signify consent and will personally date the consent document. If that is not possible, the subject will provide verbal consent.  
(4) After consent has been obtained from the subject, the person obtaining consent and the impartial witness will sign and date the written study consent form with a statement that documents that an oral  
process was used and, if necessary, that the subject provided verbal consent. By [CONTACT_73768], the witnesses attest that the information in the consent document and any other written information were accurately explained to the subject.  
(5) The consent process will also be documented in the medical record or in accord with the Institution‚Äô s 
policy.  
(6) Signed copi[INVESTIGATOR_726634].  
 HIPAA authorization will be obtained verbally, and only in cases where there is a physical limitation preventing the subject from signing his/her name. Both the waiver of documentation of consent and the verbal HIPAA authorization will be documented in the enrollment note.  
 If, at any point, the participant no longer wishes to be in this study, he/she  may notify the study investigators (as 
outlined in the consent form) and be withdrawn from the study.  
 Clinical investigation plan CS -011-004 Ver.3.1 
 32 / [ADDRESS_992380] a cognitive impairment based on their 
inability to understand and express a reasoned choice, they will be unable to provide informed consent and thus 
will be excluded from participation in the study.  
 
14 A dverse events, adverse device effects and device deficiencies 
14.1 D efinitions of adverse events and adverse device effects 
(1) Adverse event (AE) 
Any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including 
abnormal laboratory findings) in subjects, users, or other persons, whether or not related to the 
investigational medical device. This definition includes events related to the investigational medical 
device or comparator , and events related to the procedures involved. For users or other persons, this 
definition is restricted to events related to investigational medical devices.  
 
(2) Adverse device effect  (ADE)  
Adverse event related to the use of an investigational medical device. This definition includes adverse 
events resulting from insufficient or inadequate instructions for  use, deployment, implantation, 
installation, or operation, or any malfunction of the investigational medical device as well as any event resulting from use error or from intentional misuse of the investigational medical device.  
 
14.[ADDRESS_992381] and unanticipated serious 
adverse device effects  
(1) Serious adverse event (SAE) Adverse event that:  
a) led to death,  
b) led to serious deterioration in the health of the subject, that either resulted in  
1) a life -threatening illness or injury, or  
2) a permanent impairment of a body structure or a body function, or  
3) in-patient or prolonged hospi[INVESTIGATOR_059], or  
4) medical or surgical intervention to prevent life- threatening illness or injury or permanent 
impairment to a body structure or a body function,  
c) led to fetal distress, fetal death, or a congenital abnormality or birth defect  
 
 Clinical investigation plan CS -011-004 Ver.3.1 
 33 / 38 
 
NOTE: Planned hospi[INVESTIGATOR_272] a pre-existing condition, or a procedure required by [CONTACT_10396], without 
serious deterioration in health, is not considered a serious adverse event.  
 
(2) Serious adverse device effect (SADE)  
Adverse device effect that has resulted in any of the consequences characteristic of a serious adverse event.  
 
(3) Unanticipated serious adverse device effects ([LOCATION_003]DE)  
Serious adverse device effect which by  [CONTACT_5942], incidence, severity, or outcome has not been 
identified in the current version of the risk analysis report.  
 NOTE: anticipated serious adverse device effect (ASADE) is an effect which by [CONTACT_5942], incidence, severity or outcome has been identified in the risk analysis report.  
 
14.4 D efinition of unanticipated problems involving risk to subjects or others  
Any incident, experience, or outcome that meets all of the following criteria:  
‚Ä¢ Unexpected in nature, severity, or frequency  (i.e. not described in study -related documents such as the 
IRB-approved protocol or consent form, the investigators brochure, etc.) 
‚Ä¢ Related or possibly related to participation in the research (i.e. possibly related means there is a 
reasonable possibility that the incident experience, or outcome may have been caused by [CONTACT_3459])  
‚Ä¢ Suggests that the research places subjects or others at greater risk of harm  (including physical, 
psychological, economic, or social harm).  
 
14.5 T ime periods for reporting adverse events and device deficiencies  
(1) Notifying the PI [INVESTIGATOR_726635] a serious adverse event or a serious adverse device effect, and any 
type of unanticipated adverse device effect, regardless of seriousness or severity, must be reported immediately to the PI [INVESTIGATOR_726636] [ADDRESS_992382] the understanding of 
the event.  
 
(2) Notifying the IRB  
The Northwell Health IRB requires the investigators to submit reports of the following problems within 
5 working days  from the time the investigator s become aware of any adverse event that occurs any  
time during or after the study, which in the opi[INVESTIGATOR_726637]: 
 Clinical investigation plan CS -011-004 Ver.3.1 
 34 / 38 
 
‚Ä¢ Unexpected  (An event is ‚Äú unexpected‚Äù when its specificity and severity are not accurately 
reflected in the protocol -related documents, such as the IRB -approved research protocol, any 
applicable investigator brochure, and the current IRB -approved informed consent doc ument 
and other relevant sources of information, such as product labeling and package inserts.)  
AND  
‚Ä¢ Related  to the research procedures (An event is ‚Äúrelated to the research procedures‚Äù if in the 
opi[INVESTIGATOR_726638], the event was more likely than not to be caused by [CONTACT_485915].)  
The above is required regardless of whether the event is serious or non- serious, on -site or off -site. 
 
All unanticipated adverse device effects and all serious adverse device effects reported by [CONTACT_726666] s ponsor must also be reported to the IRB as soon as possible, but within 5 
business days . 
 
14.6 Process for reporting adverse events  and device deficiencies  
(1) Notifying the PI [INVESTIGATOR_726639], the investigator must seek information on adverse events including 
adverse device effects by [CONTACT_5147], as appropriate, by [CONTACT_5148]. Information on all adverse events including adverse device effects must  be recorded immediately in the source 
documents, and also in appropriate adverse event case report forms. All clearly related signs, symptoms, and abnormal diagnostic procedures results should be recorded in the source documents, though should be grouped under one diagnosis.  
 The clinical course of each event must be followed until resolution, stabilization, or until it has been determined that the study treatment or participation is not the cause. Serious adverse events and serious adverse device effects that are still ongoing at the end of the study period must be followed up to determine the final outcome. Any serious adverse device effects that occur after the study period must be recorded and reported promptly.  
 The minimum initial information to be captured in the subject ‚Äôs source documents concerning the 
adverse event includes:  
‚Ä¢ Study identifier  
‚Ä¢ Study s ubject number  
‚Ä¢ Model and serial number/lot number of the investigational device  
‚Ä¢ A description of the event  
‚Ä¢ Date of onset  
‚Ä¢ Investigator assessment of the association between the event and study procedure/treatment  
‚Ä¢ Current status  
 Clinical investigation plan CS -011-004 Ver.3.1 
 35 / 38 
 
‚Ä¢ Whether study procedure/treatment was discontinued  
‚Ä¢ Whether the event is serious and reason for classification as serious  
 
(2) Notifying the IRB  
The investigators should report unanticipated problems to the Northwell Health IRB using the form: 
‚ÄúUnanticipated Problems Posing Risks to Subjects or Others Including Reportable Adverse Events ‚Äù or 
as a written report of the event (including a description of the event with information regarding i ts 
fulfillment of the above criteria, follow- up/resolution and need for revision to consent form and/or other 
study documentation).  Copi[INVESTIGATOR_726640]‚Äôs study file. 
 <Other Reportable events > 
For clinical studies with an investigational device, the following events are also reportable to the 
Northwell Health IRB:  
‚Ä¢ For device studies that include the delivery of investigational drugs, any adverse experience 
that, even without detailed analysis, represents a serious unexpected adverse event that is rare 
in the absence of drug exposure (such as agranulocytosis, hepatic necrosis, Stevens -Johnson 
syndrome).  
‚Ä¢ Any adverse event that would cause the sponsor to modify the protocol or the informed consent form, or would prompt other action by [CONTACT_116628].  
‚Ä¢ Information that indicates a change to the risks or potential benefits of the research, in terms of severity or frequency. For example:  
o An interim analysis indicates that participants have a lower rate of response to 
treatment than initially expected.  
o Safety monitoring indicates that a particular side effect is more severe, or more frequent 
than initially expected.  
o A paper is published from  another study that shows that an arm of your research study 
is of no therapeutic value.  
‚Ä¢ Change in FDA safety labeling or withdrawal from marketing of a drug, device, or biologic used 
in a research protocol.  
‚Ä¢ Breach of confidentiality  
‚Ä¢ Change to the protocol  taken without prior IRB review to eliminate apparent immediate hazard 
to a research participant.  
‚Ä¢ Incarceration of a participant when the research was not previously approved under Subpart C and the investigator believes it is in the best interest of the subject to remain on the study.  
‚Ä¢ Complaint of a participant when the complaint indicates unexpected risks or the complaint cannot be resolved by [CONTACT_5051].  
‚Ä¢ Protocol violation (meaning an accidental or unintentional deviation from the IRB approved 
 Clinical investigation plan CS -011-004 Ver.3.1 
 36 / 38 
 
protocol) that in the opi[INVESTIGATOR_116576], 
or affects the rights or welfare of subjects.  
 
14.[ADDRESS_992383] since the applied part of the investigational device ( the 
sensor probe) is equivalent to standard pulse oximeter sensors. A well -known potential adverse effect of pulse 
oximeters is thermal injuries due to temperature rise at the applied part of the sensor.  
 
14.[ADDRESS_992384] for reporting serious adverse events and serious adverse device effects  
<Sponsor contact [CONTACT_726667] > 
Report adverse events  including adverse device effects and any unanticipated problems by [CONTACT_726668] : 
Steve Weisner, CEO  
Nihon Kohden Innovation Center  
Phone: 617 -318-5900  
Email: [EMAIL_13872] 
 
14.9 Information regarding the data monitoring committee 
Not applicable. There is no data monitoring committee for this study.  
 
15 V ulnerable population 
Not applicable. The population for this study is not  considered as a vulnerable population.  
 
16 S uspension or premature termination of the clinical investigation 
16.1 C riteria and arrangements for suspension or premature termination  
The sponsor may suspend or prematurely terminate either a clinical investigation in an individual investigation 
site (if applicable)  or the entire clinical investigation for significant and documented reasons. A principal 
investigator, IRB, or regulatory authority may suspend or prematurely terminate participation in the  clinical 
investigation at the investigation sites for which they are responsible.  
 If suspi[INVESTIGATOR_168343], or when so instructed by [CONTACT_100958], the sponsor shall suspend the clinical investigation while the risk is assessed. The sponsor shall terminate the clinical investigation if an unacceptable risk is confirmed.  The sponsor shall 
consider terminating or suspending the participation of a particular investigation site (if applicable) or investigator 
in the clinical investigation if monitoring or auditing identifies serious or repeated CIP deviations . 
 If suspension or premature termination occurs, the terminating party shall justify its decision in writing and promptly inform the other parties. The principal investigator  [INVESTIGATOR_726641] -011-004 Ver.3.1 
 37 / [ADDRESS_992385] of safety, the sponsor shall inform all other  investigators  of other investigation 
sites (if applicable).  
 
When the sponsor concludes an analysis of the reason(s) for the suspension, implements the necessary corrective actions, and decides to lift the temporary suspension, the sponsor shall inform the principal investigator, the IRB, and where appropriate, the regulatory authority of the rationale and provide them with the 
relevant data supporting this decision. Concurrence shall be obtained from the IRB and, where appropriate, regulatory authorities before the clinical investigation r esumes.  
 
16.2 C riteria for access to and breaking the blinding/masking code in the case of suspension or 
premature termination of the clinical investigation  
Not applicable. The blinding in this study is used only when CRI and CRT measurements are performed at t he 
bed side as described in the section 6.1.2: the investigator who will measure the visual CRT will be blinded from the CRI values measured with the investigational device.  
 
16.[ADDRESS_992386] be presented to the sponsor well in advance of any publication or presentation, time for the sponsor to respond to the data is encouraged and allowed per the publication policy.  
 
18 B ibliography  
1. Schriger DL, Baraff  L: Defining normal capi[INVESTIGATOR_39093]: variation with age, sex, and temperature. Ann 
Emerg Med 1988; 17:932- 935 
2. Lima A, Jansen TC, van Bommel J, et al: The prognostic value of the subjective assessment of peripheral perfusion in critically ill patients. Crit Care Med 2009; 37(3):934- 938 
3. Van Genderen ME, Paauwe J, de Jonge J, van der Valk RJP , Lima A, Bakker J, et al: Clinical assessment of peripheral perfusion to predict postoperative complications after major abdominal surgery early: a prospective observational study in adults. Crit Care  2014; 18(3): R114  
 Clinical investigation plan CS -011-004 Ver.3.1 
 38 / 38 
 
4. Alsma J, van Saase JLCM, Nanayakkara PWB, et al: The Power of Flash Mob Research: Conducting 
a Nationwide Observational Clinical Study on Capi[INVESTIGATOR_726642] a Single Day. Chest  2017; 
151:[ADDRESS_992387] A, Karlen W, Ansermino JM: Capi[INVESTIGATOR_95155]: is it still a useful clinical sign? Anesth Analg 
2011; 113:120- 123 
6. Lima A, Bakker J: Noninvasive monitoring of peripheral perfusion. Intensive Care Med 2005; 31:1316-
1326  
7. Shinozaki K, Capi[INVESTIGATOR_726643], Saeki K, et al: Blood refill time: Clinical bedside monitoring of peripheral blood 
perfusion using pulse oximetry sensor and mechanical compression. Am J Emerg Med  2018; 
36(12):2310 -2312  
8. Shinozaki K, Capi[INVESTIGATOR_726644], Saeki K, et al: Low Temperature Increases Capi[INVESTIGATOR_726645]: Prospective Cohort Study. J Clin 
Monit Comput  2018 [Epub ahead of print]  
9. Hajian -Tilaki, K.: Sample size estimation in diagnostic test studies of biomedical informatics. Journal of 
biomedical informatics  2014; 48:193- 204 
10. Obuchowski, N. A., Lieber, M. L., & Wians, F. H.: ROC curves in Clinical Chemistry: Uses, misuses, and possible solutions. Clinical Chemistry  2004; 50(7)  
11. E. A. Youngstrom . A primer on receiver operating characteristic analysis and diagnostic efficiency 
statistics for pediatric psychology: we are ready to ROC. J Pediatr Psychol . 2014;39(2):204- 221. 
 
19 Attachments 
‚Ä¢ Attachment 1: Operator‚Äôs Manual of OLV -4201  
‚Ä¢ Attachment 2: Certificate of Safety Test of  IEC [ZIP_CODE] -1 
‚Ä¢ Attachment 3: Certificate of EMC Test of IEC [ZIP_CODE] -1-2 and ISO [ZIP_CODE] -2-61(clause202)  
‚Ä¢ Attachment 4: Operator‚Äôs Manual of SpO2 sensor probe  
‚Ä¢ Attachment 5: Operator‚Äôs Manual of the CRI function  
‚Ä¢ Attachment 6: Report of Collaborative Research at Northwell  
 